Early Phase Support for Plasmid DNA Supply Helps Secure Future Manufacturing for Advanced Therapies
One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell or gene therapies that require pDNA as a starting material. Building a robust supply of GMP-grade pDNA requires that quality be a focal point of the production process. In addition, the integration of process development, manufacturing, packaging, and supply logistics of pDNA are critical to improving access and reducing timelines as this brings life-changing therapies to the patient sooner.
Watch this webinar for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technologies and strategies that drive an optimised plasmid production process and supply.
Join the webinar to learn:
Key considerations during plasmid production including design and screening systems, processing, and analytical testing
Discover how to reduce batch-to-batch inconsistencies, improve plasmid purity, and enhance plasmid yield at every stage of upstream and downstream operations
The advantages of securing plasmid bioproduction services that are fully integrated within viral vector and cell therapy manufacturing capabilities.
